Sulphasalazine + hydroxychloroquine or prednisolone (DrugBank: Prednisolone, Hydroxychloroquine)
23 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
34 | Neurofibromatosis | 0 |
41 | Giant cell arteritis | 0 |
43 | Microscopic polyangiitis | 0 |
44 | Wegener granulomatosis | 0 |
45 | Eosinophilic granulomatosis with Polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
48 | Primary antiphospholipid syndrome | 0 |
49 | Systemic lupus erythematosus | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
66 | IgA nephropathy | 0 |
84 | Sarcoidosis | 0 |
89 | Lymphangioleiomyomatosis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 0 |
218 | Alport syndrome | 0 |
222 | Primary nephrotic syndrome | 0 |
234 | Peroxisomal disease (except Adrenoleukodystrophy) | 0 |
254 | Porphyria | 0 |
271 | Ankylosing spondylitis | 0 |
298 | Hereditary pancreatitis | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02466581 (ClinicalTrials.gov) | February 3, 2015 | 29/5/2015 | Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity | A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity | Rheumatoid Arthritis | Drug: Sulphasalazine + Hydroxychloroquine OR Prednisolone;Biological: Cimzia;Biological: Orencia;Biological: RoActemra | Karolinska Institutet | NULL | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 4 | Sweden |